BACKGROUND: Antenatal corticosteroids are given primarily to induce fetal lung maturation but results from meta-analyses of randomized controlled trials have not shown mortality or pulmonary benefits for extremely preterm infants although these are the infants most at risk of mortality and pulmonary disease. OBJECTIVE: We sought to determine if exposure to antenatal corticosteroids is associated with a lower rate of death and pulmonary morbidities by 36 weeks' postmenstrual age. STUDY DESIGN: Prospectively collected data on 11,022 infants 22 0/7 to 28 6/7 weeks' gestational age with a birthweight of !401 g born from Jan. 1, 2006, through Dec. 31, 2014, were analyzed. The rate of death and the rate of physiologic bronchopulmonary dysplasia by 36 weeks' postmenstrual age were analyzed by level of exposure to antenatal corticosteroids using models adjusted for maternal variables, infant variables, center, and epoch. RESULTS: Infants exposed to any antenatal corticosteroids had a lower rate of death (2193/9670 [22.7%]) compared to infants without exposure (540/1302 [41.5%]) (adjusted relative risk, 0.71; 95% confidence interval, 0.65e0.76; P < .0001). Infants exposed to a partial course of antenatal corticosteroids also had a lower rate of death (654/2520 [26.0%]) compared to infants without exposure (540/1302 [41.5%]); (adjusted relative risk, 0.77; 95% confidence interval, 0.70e0.85; P < .0001). In an analysis by each week of gestation, infants exposed to a complete course of antenatal corticosteroids had lower mortality before discharge compared to infants without exposure at each week from 23-27 weeks' gestation and infants exposed to a partial course of antenatal corticosteroids had lower mortality at 23, 24, and 26 weeks' gestation. Rates of bronchopulmonary dysplasia in survivors did not differ by antenatal corticosteroid exposure. The rate of death due to respiratory distress syndrome, the rate of surfactant use, and the rate of mechanical ventilation were lower in infants exposed to any antenatal corticosteroids compared to infants without exposure. CONCLUSION: Among infants 22-28 weeks' gestational age, any or partial antenatal exposure to corticosteroids compared to no exposure is associated with a lower rate of death while the rate of bronchopulmonary dysplasia in survivors did not differ.
Introduction
The effects of antenatal corticosteroids on mortality and pulmonary outcomes at the lowest gestations show mixed results, in part due to the small sample size of randomized controlled trials. 1, 2 Although antenatal corticosteroids are given primarily to induce pulmonary maturity, induce surfactant release, and decrease respiratory distress syndrome, randomized controlled trials and meta-analyses of antenatal corticosteroids show no reduction in respiratory distress syndrome or neonatal death for infants delivered <30 weeks' gestation. 1, 2 In addition, there are limited data from observational studies comparing the pulmonary outcomes of extremely preterm infants exposed to antenatal corticosteroids to those without exposure because these studies have not been focused on pulmonary outcomes. [3] [4] [5] [6] [7] [8] Extremely preterm infants who die <36 weeks' postmenstrual age cannot be assessed for the development of bronchopulmonary dysplasia, a type of chronic lung disease that is diagnosed at 36 weeks' postmenstrual age. 9 It is important to evaluate the competing outcomes of bronchopulmonary dysplasia and death both together and separately. Antenatal corticosteroid exposure may affect both outcomes for example if more infants survive following exposure and then develop bronchopulmonary dysplasia subsequently.
A complete course of antenatal corticosteroids is defined as 2 intramuscular doses of betamethasone given 12-24 hours apart or 4 intramuscular doses of dexamethasone given 12 hours apart. 10 Many preterm infants are born prior to the administration of a complete course of antenatal corticosteroids. 11, 12 There are insufficient data on mortality and pulmonary outcomes of extremely preterm infants born after exposure to either a complete or a partial course of antenatal corticosteroids. We hypothesized that the rates of death would be lower in infants exposed to antenatal corticosteroids. In addition, we hypothesized that the rates of physiologic bronchopulmonary dysplasia or death would be lower in infants exposed to antenatal corticosteroids. This study was also designed to determine if exposure to a partial or a complete course of antenatal corticosteroids is associated with improved survival and pulmonary outcomes in extremely preterm infants.
Materials and Methods
This was a hypothesis-driven study using data collected prospectively for the Neonatal Research Network Generic Database and follow-up studies. These data included infants 22 0/7 to 28 6/7 weeks' gestation with a birthweight of !401 g born from Jan 1, 2006 , through Dec. 31, 2014 , at any of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Neonatal Research Network centers. Maternal and neonatal sociodemographic and clinical data were collected from medical records by trained research personnel. Gestational age was determined by best obstetric estimate over best neonatal estimate. 13 Infants with congenital anomalies were included if they were resuscitated as these infants were less likely to have lethal anomalies. Infants who died in the first 12 hours after birth without delivery room resuscitation were excluded from the primary analysis to ensure that results were not affected by planned restriction of care but were included in a secondary analysis. The study protocol was approved by each center's institutional review board. ClincalTrials.gov identifiers are: NCT00063063 (generic database) and NCT00009633 (follow-up study).
Definitions
Infants were considered exposed to antenatal corticosteroids if their mother had received !1 doses of either betamethasone or dexamethasone. 10 Mothers were considered to have received a complete course if they had received at least 2 doses and 24 hours had passed from the time the first dose of antenatal corticosteroids was given. Data on repeat courses of antenatal corticosteroids were not collected.
14 Data were collected using standardized definitions until death or discharge. Follow-up data were collected using standardized definitions on eligible surviving infants at 18-22 months corrected gestational age. Bronchopulmonary dysplasia was defined based on respiratory support at 36 weeks' postmenstrual age using the physiologic definition, which uses an oxygen reduction challenge test among eligible infants. 15 The physiologic definition has been shown to be more reliable and precise than the clinical definition of bronchopulmonary dysplasia 15 (defined as supplemental oxygen at 36 weeks' postmenstrual age) and has been used by the Neonatal Research Network since 2006. All other outcomes were based on standardized definitions as per the generic database of the Neonatal Research Network. 16 Cause of death was defined as the underlying proximate disease that initiated the series of events leading to death based on both clinical evidence and autopsy findings where available. 13 
Statistical analysis
The primary outcome measure was death before discharge. A formal sample size and power estimate demonstrated that the sample size resulting from inclusion of all infants delivered from Jan. 1, 2006 1, , through Dec. 31, 2014 , would provide >95% power to detect an absolute difference of 4% centered around an overall event rate of 25%. All secondary outcome measures and analyses were prespecified. All outcomes were analyzed by level of exposure to antenatal corticosteroid: complete exposure, partial exposure, any (partial or complete) exposure, and no exposure. Differences in categorical variables were described using Fisher exact test. Kruskal-Wallis test was used for continuous skewed variables. Robust Poisson regression analysis was performed for factors present at birth associated with pulmonary outcomes including birthweight, sex, multiple births, small for gestational age (<10th centile), maternal variables (age, marital status, race, diabetes, rupture of membranes !24 hours, antepartum hemorrhage, and mode of delivery), center, and epoch (2006 through 2009, and 2010 through 2014) . [17] [18] [19] There were 0.5% missing data for the primary outcome and 9.7% missing data for the follow-up outcomes at 18-22 months corrected gestational age. To ensure that results were not affected by missing data, multiple imputation analyses were FIGURE 1 Frequency of antenatal corticosteroids exposure by gestational age and year
Frequency of exposure to antenatal corticosteroids (ANS) by gestational age and year of birth. Administration of ANS increased over study period but remained lower at lower gestational ages. ajog.org OBSTETRICS Original Research additionally conducted for outcomes with >1% of data missing, or when there was an imbalance of missing data of >0.3% between groups. An additional analysis was also performed adjusting for chorioamnionitis (diagnosed by placental pathology). This separate analysis was not performed by each week of gestation. Software (SAS, Version 9.3; SAS Institute Inc, Cary, NC) was used for all statistical analyses. Odds ratios and 95% confidence intervals (CI) were estimated for binary outcomes with a 2-sided P value of <.05 indicating statistical significance.
Results
A total of 11,022 infants met the inclusion criteria of whom 9715 (88.1%) were exposed to antenatal corticosteroids. The proportion of infants at each gestational age from 23-28 weeks exposed to antenatal corticosteroids increased over the study period ( Figure 1 ). Mothers of infants exposed to antenatal corticosteroids were more likely to be white, delivered by cesarean delivery, with private health insurance. Infants exposed to antenatal corticosteroids had higher birthweight, had longer gestational age, and were more likely to be small for gestational age and the product of multiple births (Table 1) .
Infants exposed to any antenatal corticosteroids had lower mortality before discharge (2193/9670 [22 Table 2 ). Infants exposed to a partial course of antenatal corticosteroids also had lower mortality before discharge compared to infants without exposure (Supplementary Table 1 ). In the analysis by each week of gestation, infants exposed to a complete course of antenatal corticosteroids had lower mortality before discharge compared to infants without exposure at each week from 23-27 weeks' gestation ( Figure 2 and Table 3 ). Infants exposed to a partial course of antenatal corticosteroids had lower mortality at 23, 24, and 26 weeks' gestation ( Figure 2 and Table 3 ).
Infants exposed to any antenatal corticosteroids had a lower rate of physiologic bronchopulmonary dysplasia or death by 36 weeks' postmenstrual age (6016/9579 [62.8%]) compared to infants without exposure (940/1300 [72.3%]) (ARR, 0.94; 95% CI, 0.91e0.98; P ¼ .001) ( Table 2 ). The rate of physiologic bronchopulmonary dysplasia or death by 36 weeks' postmenstrual age did not differ among infants exposed to a partial course of antenatal corticosteroids compared to infants without exposure (Supplementary Table 1 ). The rate of physiologic bronchopulmonary dysplasia among survivors at 36 weeks' postmenstrual age did not differ significantly in infants exposed to any antenatal corticosteroids compared to infants without exposure ( Table 2 ). The rate of death due to bronchopulmonary dysplasia did not differ significantly in infants exposed to any antenatal corticosteroids (172/9661 [1.8%]) compared to infants without exposure (16/1299 [1.2%] ) (ARR, 1.65; 95% CI, 0.96e2.83;
The rate of respiratory distress syndrome did not differ in infants exposed to any antenatal corticosteroids compared to infants without exposure ( Table 2 ). The rate of death due to respiratory distress syndrome was lower in infants exposed to any antenatal corticosteroids compared to infants without exposure ( Table 2 ). The rate of death due to respiratory distress syndrome was also lower in infants exposed to a complete or partial course of antenatal corticosteroids compared to infants without exposure (Supplementary Table 1 ). The rate of surfactant use and the rate of mechanical ventilation were lower in infants exposed to any antenatal corticosteroids compared to infants without exposure (Table 2 ). Infants exposed to any antenatal corticosteroids had a lower rate of severe intracranial hemorrhage/periventricular leukomalacia and severe retinopathy of prematurity compared to infants without exposure ( Table 2 ). The rate of pulmonary hemorrhage, pneumothorax, early-onset sepsis, proven necrotizing enterocolitis, patent ductus arteriosus treated with indomethacin/ ibuprofen, treatment with postnatal steroids for bronchopulmonary dysplasia, and prolonged hospital stay did not differ by antenatal corticosteroids exposure (Table 2) . Among survivors exposed to any antenatal corticosteroids there was a higher rate of oxygen therapy at discharge compared to infants without exposure but among (Table 2) .
Infants exposed to a complete course of antenatal corticosteroids had a lower rate of death before discharge compared to infants exposed to a partial course of antenatal corticosteroids (Supplementary Table 1 ). Infants exposed to a complete course of antenatal corticosteroids also had a lower rate of death due to respiratory distress syndrome, surfactant use, mechanical ventilation, severe intracranial hemorrhage/periventricular leukomalacia, and pulmonary hemorrhage compared to infants exposed to a partial course of antenatal corticosteroids (Supplementary Table 1 ).
The inclusion of the 883 infants who died within 12 hours without receiving delivery room resuscitation strengthened the association between lower mortality and exposure to antenatal corticosteroids, particularly among infants at the lowest gestations (Supplementary Table 2 ). The results of the models using multiple imputation for missing data were substantively similar to the primary analysis (Supplementary Table 3 ). The results of the models that included chorioamnionitis did not substantively differ and are not presented.
Comment

Principal findings
This large multicenter observational study shows that exposure to a complete or partial course of antenatal corticosteroids is associated with lower mortality in infants 22-28 weeks' gestation and weighing !401 g after adjustment for multiple confounders. Among survivors, the rate of bronchopulmonary dysplasia in infants exposed to either a complete or partial course of antenatal corticosteroids did not differ compared to infants who were not exposed. Although all groups had a high rate of respiratory distress syndrome, there was a lower rate of death due to respiratory distress syndrome and a lower use of surfactant and mechanical ventilation among infants exposed to antenatal corticosteroids indicating amelioration of the course of respiratory distress syndrome.
Meaning/clinical implications of findings
The current study demonstrates a lower rate of death associated with exposure to antenatal corticosteroids in infants <29 weeks' gestation. Randomized controlled trials of administration of antenatal corticosteroids to women who delivered at <30 weeks' gestation show inconclusive neonatal outcomes, in part due to small sample size. 1, 2 In the Cochrane review subgroup analysis of those infants <28 weeks' gestation, 1 there was no significant reduction in the rate of neonatal death but the sample was small (2 studies, 89 infants). The current study agrees with data from observational studies that show a survival benefit among extremely preterm infants at the lowest gestations. 20 Many of the studies included in the meta-analyses of randomized controlled trials 1, 2 were carried out in the era before the widespread use of surfactant and when the methods of ventilatory support used were different. 21, 22 In the Cochrane review subgroup analysis of those infants <28 weeks' gestation, there was no significant reduction in the rate of respiratory distress syndrome (4 studies, 102 infants). 1 Rates of bronchopulmonary dysplasia were not analyzed by gestational age at delivery but were not different for the cohort as a whole (6 studies, 818 infants). In the current study, the rates of respiratory distress syndrome and the rates of bronchopulmonary dysplasia among survivors were also not different.
Observational studies have shown marked variability in pulmonary outcomes in infants at the lowest gestations. A NICHD Neonatal Research Network study including 10,541 infants delivered between 22-25 weeks' gestation found that a lower mortality rate associated with exposure to antenatal corticosteroids was partially offset by a higher rate of bronchopulmonary dysplasia among survivors compared to infants without exposure. 3 A multicenter study of 2549 infants <29 weeks' gestation also found that the rate of bronchopulmonary dysplasia was higher in infants exposed to a complete course of antenatal Death before discharge by antenatal corticosteroid exposure Death before discharge of infants 22-28 weeks' gestation by antenatal corticosteroid (ANS) exposure. Infants exposed to course of ANS had lower rate of death before discharge compared to infants who were not exposed to ANS at each gestational age from 23-27 weeks. Infants exposed to partial course of ANS had lower mortality at 23, 24, and 26 weeks' gestation. Original Research OBSTETRICS ajog.org 4 Another multicenter study of 11,607 infants born 22-33 weeks' gestation found that the rates of bronchopulmonary dysplasia did not differ in infants exposed to any antenatal corticosteroids compared to infants without exposure. 5 These differences in bronchopulmonary dysplasia rates may be related to the different definition of bronchopulmonary dysplasia 9 used in these studies as well as the gestational age inclusion criteria as inclusion of infants at the lowest gestations would result in more survivors who can develop bronchopulmonary dysplasia.
An important focus of the current study was the differential benefits of a partial or a complete course of antenatal corticosteroids. Although a complete course of antenatal corticosteroids is associated with a lower mortality compared to a partial course, the current study indicates that the first dose of antenatal corticosteroids may have the largest effect on reducing mortality. The Cochrane review of randomized controlled trials subgroup analysis of infants delivered following a partial course of antenatal corticosteroids showed a significant reduction in neonatal death in infants exposed to a partial course (4 studies, 295 infants). 1 The current study results are in concordance with those of an observational study of 9949 infants weighing 501-1500 g from the era before widespread use of antenatal corticosteroids and surfactant that found a lower rate of death before discharge in infants exposed to a partial course of antenatal corticosteroids compared to infants without exposure. 6 In that study the rate of bronchopulmonary dysplasia also did not differ by degree of exposure to antenatal corticosteroids. The aforementioned study by Wong et al 4 indicated that mortality did not differ in infants exposed to a partial course of antenatal corticosteroids compared to infants without exposure but this study was limited by a relatively small sample size.
Strengths and weaknesses
This study used data collected from top academic centers across the United States where optimal obstetric and neonatal care might be anticipated but there are several limitations that should be noted. There was no inception cohort of fetuses exposed or not exposed to antenatal corticosteroids. Data were not available on the exact timing of antenatal corticosteroids, whether fetal monitoring was undertaken prior to delivery, or the length of maternal hospitalization before delivery. 23 There is a risk of bias as women admitted in advanced labor most likely would be overrepresented in the group that did not receive antenatal corticosteroids. While it is also unlikely that the results of this study are only due to confounding, there may be some residual unmeasured bias in the results due to baseline differences between the study groups that may not be adequately adjusted for in the models used. In addition, there is a possibility of postnatal bias in which infants not exposed to antenatal corticosteroids may have had their care restricted or withheld, particularly among infants at the lowest gestations. To reduce this effect, infants who died within 12 hours of birth without receiving delivery room resuscitation were excluded from the primary analysis. The multiple testing used in this study at a 5% significance level may have resulted in a few results being significant purely by chance. However, the benefits were consistent at most gestations, suggesting that the results are not only due to chance.
Research implications
Although antenatal corticosteroid administration reduces preterm infant mortality and morbidity without increasing the cost of care, 1 many eligible women 24 do not receive this treatment. 11, 12 Center differences in the use of antenatal corticosteroids are associated with mortality among infants at the lowest gestations. 25, 26 Differences between administration rates among infants by gestation in this study indicate that although administration rates are increasing, there are opportunities for quality improvement. Original Research OBSTETRICS ajog.org
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Conclusion
The current study demonstrates that antenatal exposure to corticosteroids for infants 22 0/7 to 28 6/7 weeks' gestation is associated with a lower rate of death before discharge without a higher rate of bronchopulmonary dysplasia or other major adverse pulmonary problems. This study also indicates that antenatal corticosteroids ameliorate the severity of respiratory distress syndrome and other important morbidities in extremely preterm infants. n SUPPLEMENTARY 
